You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
成都先導(688222.SH):正在基於已有基礎開發擁有自主知識產權的核酸藥物遞送系統
格隆匯 05-24 11:15

格隆匯5月24日丨有投資者向成都先導(688222.SH)提問:公司的核酸藥物研發平台進展如何?

成都先導回覆:您好,感謝您對公司的關注!公司由核酸藥物研發專家組成的核酸藥物研發平台,涵蓋若干關鍵領域,包括生物信息學、核酸藥物化學、RNA生物學、分子與細胞生物學、轉化研究等。該平台具備從治療靶點出發,發現和開發寡聚核酸臨牀候選化合物的能力,可以為合作伙伴進行“一站式”的寡聚核酸藥物發現,現已經得到部分市場的認可;此外,該平台可以提供高質量的定製化的寡聚核酸相關技術服務,包括快速平行合成與化學修飾,基因敲除活性測試、穩定性測試、脱靶風險評估及核酸藥物體內分佈及其他體內外生物功能評價等。

另外,公司已經建立的成熟可靠的編碼/解碼系統和多樣性巨大的分子庫,為篩選和開發核酸藥物遞送系統配方和組織、細胞特異性配體提供了可能。公司正在基於已有基礎,開發擁有自主知識產權的核酸藥物遞送系統。謝謝!

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account